CA-based Pelage secures $16.75million in series A round funding. Leading the round was GV, with participation from YK BioVentures, Main Street Advisors, and Visionary Ventures.
The funding will be used by the company to develop a first-in-class treatment for alopecia, which includes chemotherapy-induced hair loss and androgenetic alopecia, also known as pattern baldness.
Read also – CA-based Trianz Secures a Major Growth Equity Investment
Pelage Pharmaceuticals, a clinical-stage regenerative medicine firm led by CEO Daniel Gil, is creating innovative therapeutics for androgenetic alopecia and chemotherapy-induced alopecia.
It is developing a novel class of medicines that aim to stimulate latent hair follicle stem cells and restore the body’s natural ability to create hair, with a focus on molecular and stem cell biology. PP405, its flagship programme, is presently undergoing clinical testing.
Daniel Gil said: “We are pleased to announce that we have completed a first-in-human Phase 1 clinical trial that demonstrated seven days of topical dosing with PP405 was safe and well-tolerated, and showed statistically significant activation of hair follicle stem cells. With the support of GV, Main Street Advisors and other top-tier investors, we expect to advance our lead program to a Phase 2a clinical trial in the second half of this year.”
About Pelage Pharmaceuticals
Pelage Pharmaceuticals is a clinical-stage regenerative medicine startup creating innovative hair loss treatments, such as androgenetic alopecia and alopecia brought on by chemotherapy. Pelage is developing a novel class of treatments centred on molecular and stem cell biology that aim to rejuvenate dormant hair follicle stem cells and bring back the body’s capacity for natural hair growth.
Read also – PA-based Abridge Secures an Additional $150Million Funding
